The discovery and optimisation of benzazepine sulfonamide and sulfones as potent agonists of the motilin receptor

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 22, 2009, Pages 6452-6458

  Bailey, James M ^a   Scott, Jackie S ^a   Basilla, Jonathan B ^b   Bolton, Victoria J ^a   Boyfield, Izzy ^a   Evans, David G ^a   Fleury, Etienne ^a   Heightman, Tom D ^a   Jarvie, Emma M ^a   Lawless, Kirk ^a   Matthews, Kim L ^a   McKay, Fiona ^a   Mok, Hindy ^a   Muir, Alison ^a   Orlek, Barry S ^a   Sanger, Gareth J ^a   Stemp, Geoffrey ^a   Stevens, Alexander J ^a   Thompson, Mervyn ^a   Ward, John ^a   Vaidya, Kalindi ^b   Westaway, Susan M ^a   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

7TM; Agonist; Benzazepine; Motilin

Indexed keywords

BENZAZEPINE DERIVATIVE; BENZAZEPINE SULFONAMIDE; GHRELIN RECEPTOR; MOTILIN; MOTILIN RECEPTOR; PYRAZOLE DERIVATIVE; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

AGONIST; ARTICLE; HIGH THROUGHPUT SCREENING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; CHEMISTRY, PHARMACEUTICAL; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; DRUG DISCOVERY; MODELS, CHEMICAL; MOLECULAR STRUCTURE; RECEPTORS, GASTROINTESTINAL HORMONE; RECEPTORS, NEUROPEPTIDE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; SULFONES;

EID: 71049158821     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.09.027     Document Type: Article

References (35)

1. Poitras P., and Peeters T.L. Curr. Opin. Endocrinol. 15 (2008) 54
2. Itoh Z. Peptides 18 (1997) 593
3. Huang J., Zhou H., Mahavadi S., Sriwai W., Lyall V., and Murthy K.S. Am. J. Physiol. Gastrointest. Liver Physiol. 288 (2005) G23
4. Christofides N.D., Modlin I.M., Fitzpatrick M.L., and Bloom S.R. Gastroenterology 76 (1979) 903
5. Schmid R., Schusdziarra V., Allescher H.-D., Bofilias I., Buttermann G., and Classen M. Diabetes Care 14 (1991) 65
6. Vantrappen G., Janssens J., Peeters T.L., Bloom S.R., Christofides N.D., and Hellemans J. Dig. Dis. Sci. 24 (1979) 497
7. Tomasetto C., Karam S.M., Ribieras S., Masson R., Lefebvre O., Staub A., Alexander G., Chenard M.-P., and Rio M.-C. Gastroenterology 119 (2000) 395
8. Kojima M., Hosoda H., Date Y., Nakazato M., Matsuo H., and Kangawa K. Nature 402 (1999) 656
9. McKee K.K., Tan C.P., Palyha O.C., Liu J., Feighner S.D., Hreniuk D.L., Smith R.G., Howard A.D., and Van der Ploeg L.H.T. Genomics 46 (1997) 426
10. Feighner S.D., Tan C.P., McKee K.K., Palyha O.C., Hreniuk D.L., Pong S.-S., Austin C.P., Figueroa D., MacNeil D., Cascieri M.A., Nargund R., Bakshi R., Abramovitz M., Stocco R., Kargman S., O'Neill G., Van Der Ploeg L.H.T., Evans J., Patchett A.A., Smith R.G., and Howard A.D. Science 284 (1999) 2184
11. Quigley E.M.M. Aliment. Pharmacol. Ther. 20 (2004) 56
12. Peeters T., Matthijs G., Depoortere I., Cachet T., Hoogmartens J., and Vantrappen G. Am. J. Physiol. Gastrointest. Liver Physiol. 257 (1989) G470
13. Janssens J., Peeters T.L., Vantrappen G., Tack J., Urbain J.L., De Roo M., Muls E., and Bouillon R.N. Eng. J. Med. 322 (1990) 1028
14. Ray W.A., Murray K.T., Meredith S., Narasimhulu S.S., Hall K., and Stein C.M.N. Eng. J. Med. 351 (2004) 1089
15. Tack J., and Peeters T. Gut 49 (2001) 317
16. Peeters T.L. Neurogastroenterol. Motil. 18 (2006) 1
17. Peeters T.L. Curr. Opin. Investig. Drugs 2 (2001) 555
18. McCallum R.W., and Cynshi O. Aliment. Pharmacol. Ther. 26 (2007) 1121
19. McCallum R.W., and Cynshi O. Aliment. Pharmacol. Ther. 26 (2007) 107
20. Heightman T.D., Conway E., Corbett D.F., MacDonald G.J., Stemp G., Westaway S.M., Celestini P., Gagliardi S., Riccaboni M., Ronzoni S., Vaidya K., Butler S., McKay F., Muir A., Powney B., Winborn K., Wise A., Jarvie E.M., and Sanger G.J. Bioorg. Med. Chem. Lett. 18 (2008) 6423
21. Westaway S.M., Brown S.L., Conway E., Heightman T.D., Johnson C.N., Lapsley M.K., MacDonald G.J., MacPherson D.T., Mitchell D.J., Myatt J.W., Seal J.T., Stanway S.J., Stemp G., Thompson M., Celestini P., Colombo A., Consonni A., Gagliardi S., Riccaboni M., Ronzoni S., Briggs M.A., Matthews K.L., Stevens A.J., Bolton V.J., Boyfield I., Jarvie E.M., Stratton S.L., and Sanger G.J. Bioorg. Med. Chem. Lett. 18 (2008) 6429
22. Westaway S.M., Brown S.L., Fell S.C.M., Johnson C.N., MacPherson D.T., Mitchell D.J., Myatt J.W., Stanway S.J., Seal J.T., Stemp G., Thompson M., Lawless K., McKay F., Muir A.I., Barford J.M., Cluff C., Mahmood S.R., Matthews K.L., Mohamed S., Smith B., Stevens A.J., Bolton V.J., Jarvie E.M., and Sanger G.J. J. Med. Chem. 52 (2009) 1180
23. Li J.J., Chao H.-G., Wang H., Tino J.A., Lawrence R.M., Ewing W.R., Ma Z., Yan M., Slusarchyk D., Seethala R., Sun H., Li D., Burford N.T., Stoffel R.H., Salyan M.E., Li C.Y., Witkus M., Zhao N., Rich A., and Gordon D.A. J. Med. Chem. 47 (2004) 1704
24. For details of the motilin receptor agonist FLIPR assay, see Ref. 20a.
25. For details of the rabbit isolated gastric antrum native tissue assay, see:. Jarvie E.M., North Laidler V.J., Corcoran S., Bassil A., and Sanger G.J. Brit. J. Pharmacol. 150 (2007) 455
26. For details of the ghrelin receptor agonist assay, see:. Heightman T.D., Scott J.S., Longley M., Bordas V., Dean D.K., Elliott R., Hutley G., Witherington J., Abberley L., Passingham B., Berlanga M., de los Frailes M., Wise A., Powney B., Muir A., McKay F., Butler S., Winborn K., Gardner C., Darton J., Campbell C., and Sanger G. Bioorg. Med. Chem. Lett. 17 (2007) 6584
27. For representative procedures for determining P450 inhibition and intrinsic clearance, see:. Michell F., Bonanomi G., Blaney F.E., Braggio S., Capelli A.M., Checchia A., Curcuruto O., Damiani F., Di Fabio R., Donati D., Gentile G., Gribble A., Hamprecht D., Tedesco G., Terreni S., Tarsi L., Lightfoot A., Stemp G., MacDonald G., Smith A., Pecoraro M., Petrone M., Perini O., Piner J., Rossi T., Worby A., Pilla M., Valerio E., Griffante C., Mugnaini M., Wood M., Scott C., Andreoli M., Lacroix L., Schwarz A., Gozzi A., Bifone A., Ashby C., Hagan J., and Heidbreder C. J. Med. Chem. 50 (2007) 5076
28. Several crystal structures of heme oxygenase 1 (HO-1) in complex with imidazole based inhibitors exhibiting a common binding mode via imidazole NH hydrogen bonding to the heme core have recently been described:. Rahman M.N., Vlahakis J.Z., Vukomanovic D., Szarek W.A., Nakatsu K., and Jia Z. J. Med. Chem. 52 (2009) 4946
29. Rahman M.N., Vlahakis J.Z., Szarek W.A., Nakatsu K., and Jia Z. J. Med. Chem. 51 (2008) 5943
30. Sugishima M., Higashimoto Y., Oishi T., Takahashi H., Sakamoto H., Noguchi M., and Fukuyama K. Biochemistry 46 (2007) 1860
31. Bonanomi, G.; Cardullo, F.; Damiani, F.; Gentile, G.; Hamprecht, D.; Michell, F.; Tarsi, L. WO 2006/002928 A1.
32. Gabriel, S. Ber. Dtsch. Chem. Ges. 1881, 14, 833.
33. Parr, C. A.; Pickering, P. L.; Sehmi, S. S.; Wilson, D. M. WO2006/018260 A1.
34. +).
35. Gleeson M.P. J. Med. Chem. 51 (2009) 817